HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China
29 avr. 2021 02h00 HE
|
Hutchison China MediTech Limited
— Single-arm study in ~180 patients, with ORR as primary endpoint — — Relapsed/refractory FL and MZL constitute approximately 25% of all NHL — — HMPL-689 trials are also underway in these and...
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
08 avr. 2021 03h30 HE
|
Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG...
HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies
29 mars 2021 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated two international Phase I...
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
24 mars 2021 09h30 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it has reached an...
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
24 mars 2021 03h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib in...
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity
04 mars 2021 07h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), an innovation-driven, commercial-stage...
Chi-Med to Announce 2020 Final Results
03 févr. 2021 02h00 HE
|
Hutchison China MediTech Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its final results for the...
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
14 janv. 2021 05h00 HE
|
Hutchison China MediTech Limited
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the final analysis of savolitinib in...
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
10 janv. 2021 20h00 HE
|
Hutchison China MediTech Limited
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals...
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
30 déc. 2020 07h00 HE
|
Hutchison China MediTech Limited
– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China – – The pivotal Phase III SANET-ep trial...